Industry · Pharmaceuticals

India's pharma supply chain
runs on 60-day credit.
We make it run on cash.

From manufacturer to distributor to retailer — every tier waits. Every tier is over-leveraged. Every tier's working capital is locked in the tier below it. LedgerNexa instruments the chain and unlocks the credit.

60–90d
Manufacturer-to-distributor credit cycle
₹4T+
Indian pharma market size (2024)
3+
Intermediary tiers in distribution
0
Tier-2/3 suppliers with ERP-backed financing
The Problem

A classic multi-tier
credit trap.

India's pharma supply chain is built on layered credit extensions — each tier borrowing time from the next. The goods are real. The credit is locked.

🏭
Manufacturer
extends 60–90d
📦
C&F Agent
extends 45–60d
🚚
Distributor
extends 30–45d
🏪
Retailer
waits 30d
🏥
Hospital / HCP
end buyer
🧊
Cold Chain Complexity
Temperature-sensitive products require compliance documentation across every hand-off — creating financing friction even when the underlying credit risk is low.
📋
GST & CDSCO Burden
Multiple GSTIN registrations across state C&F points, CDSCO batch tracking requirements, and DPCO price compliance create a documentation overhead that small distributors can't manage alone.
⚠️
Perishable Collateral Problem
Inventory has expiry. Banks don't know how to value it. LedgerNexa's deterioration-adjusted inventory model solves this — turning expiry risk into a dynamic credit signal instead of a financing barrier.
How LedgerNexa Applies

Instrument → Finance → Risk,
pharma-calibrated.

Module 01
Instrument · Pharma
Batch-level inventory tracking with expiry date management
Cold chain compliance event logging (temperature breaches, time stamps)
CDSCO-compliant documentation flow inside ERP
C&F agent and distributor onboarding with Udyam + multi-GSTIN verification
DPCO price compliance flag (regulatory risk signal)
Module 02
Finance · Pharma
Reverse factoring on manufacturer-to-distributor invoices (manufacturer = credit anchor)
PO financing for distributors placing orders with manufacturers
Tiered payment: partial advance on dispatch, balance on cold chain acceptance — optimises both sides
TReDS eligibility for qualified distributors and C&F agents
IBDIC InvoiceHub integration for verified invoice presentation
Module 03
Risk · Pharma
Expiry-adjusted inventory valuation — deteriorating asset model calibrated per drug category
Inventory turnover velocity as primary credit signal (high turnover = low credit risk)
Distributor DSO monitoring with early warning on cash flow deterioration
Supply chain correlation risk — domino-default detection across distributor networks
Regulatory risk flags (DPCO, CDSCO, state drug licence status)
Why Now

The policy window
is open.

The government's push for Jan Aushadhi, ONDC's pharma vertical expansion, and TReDS eligibility extensions for pharma MSMEs create a structural window. GSTN e-invoicing mandates are forcing formalisation down the chain — and formalisation is the prerequisite for financing.

LedgerNexa is designed to be the operating layer that connects these rails for the pharma distribution chain — before the window closes and incumbents consolidate.

Structural tailwinds
Jan Aushadhi₹10,000 Cr+ procurement push
ONDC PharmaSeller NP for pharma MSMEs
TReDS expansionMSME threshold reduced to ₹500 Cr buyer
e-Invoicing mandateForced formalisation = financing eligibility
OCEN phase 2API-based lending for pharma inventory cycles

Interested in piloting LedgerNexa
in your pharma supply chain?

We are looking for pharma manufacturers, C&F agents, and distributors for our pilot cohort.

Connect With Us →